This is the guy you want leading commercialization of your 1st FDA approved GH drug
Philip J. Young
Executive Vice President of Commercial Operations and Chief Business Officer
In March of 2004, Mr. Young was appointed Executive Vice President of Commercial Operations and Chief Business Officer of Insmed Incorporated. Mr. Young brings over 20 years of successful pharmaceutical experience in product development, launch and commercialization to Insmed. Prior to joining Insmed, Mr. Young served in various senior executive positions, including President and Chief Executive Officer, for early stage biotechnology companies. From 1998-2000, Mr. Young was Vice President and General Manager of Neurex Pharmaceuticals, where he was responsible for developing and managing the commercial and clinical strategies for new product launches and expanding label indications. Mr. Young played a key role in the $750 million acquisition of Neurex by Élan. Prior to Neurex, Mr. Young was Business Director and General Manager of the Peptide Hormones Division at Pharmacia (Pfizer) where under his leadership strategies were developed which led to the successful launch of Genotropin for pediatric and adult growth hormone deficiency. Mr. Young also served for seven years at Genentech where he was the Product Manager of Growth Hormone Products. Mr. Young was an integral member of the team that managed the FDA regulatory pathway and commercial launch for Nutropin, Genentech’s growth hormone product.
Ze hebben een topper binnen gehaald met deze man!!